ClinicalTrials.gov
ClinicalTrials.gov Menu

Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma (FULIMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02187731
Recruitment Status : Active, not recruiting
First Posted : July 11, 2014
Last Update Posted : August 29, 2018
Sponsor:
Information provided by (Responsible Party):
Brian Oestergaard, Odense University Hospital

Brief Summary:

The FULIMA study is a two-center study at Odense University Hospital and Vejle Hospital, Denmark. The primary objective is to identify the optimal imaging technique for studies in multiple myeloma with focus on PET/CT and MRI.

By combining early (1 hour) and late (3 hours) 18F-2-fluoro-2-deoxy-D- fluorodeoxyglucose(18F-FDG)-PET/CT scans the investigators expect to see increased uptake of radioactive tracer and thus an improved ability to identify malignant tissue. A second tracer 18F-natrium-fluoride is used to explore early signs of bone remodeling. By using new software (ROVER) for interpreting PET data the investigators expect to obtain a quantitative measurement of total disease burden with less risk of misinterpretation of data.

Diffusion weighted MRI (DWI) is a new MRI technique which, like PET/CT, makes it possible quantitatively to calculate the overall disease activity and to give an early evaluation of response to chemotherapy. The study examines DWI for development and standardization.

To validate imaging findings and to explore the pathogenetic heterogeneity of multiple myeloma, the investigators perform CT guided biopsies from PET/ DWI positive sites. Pathoanatomical and immunohistochemical findings and gene expression data from positive sites are compared to random bone marrow. The question is whether disease heterogeneity may explain the lack of FDG uptake in bone marrow in some patients? To the extent that the FULIMA study produces useful data, the defined and standardized imaging techniques will form the basis of a larger prospective study at national level in Denmark.


Condition or disease
Multiple Myeloma

Study Type : Observational
Actual Enrollment : 70 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: FULIMA - A Prospective Study of Dual Time PET/CT and Diffusion Weighted MRI in Multiple Myeloma
Actual Study Start Date : June 2013
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Multiple myeloma identified as bone disease, myeloma or plasmacytoma [ Time Frame: "baseline" ]
    A 1st complete set of imaging procedures is completed at time of diagnosis "baseline" (week 1-2) for all patients included in the study. The primary hypothesis that 3-hour FDG-PET / CT finds more malignant lesions than the current gold standard procedure, whole body x-ray(WBXR), together with CT and MRI. Concordance analysis will be done by summarizing comparisons of 3-hours FDG-PET/CT versus the remaining modalities. We measure a 95% Wilson-Score Confidence Interval (CI) to demonstrate that 3hours FDG-PET / CT find more malignant lesions than gold standard. This will be concluded at a significance level of 5% if the lower boundary of the 95% CI is larger than 30%.


Secondary Outcome Measures :
  1. Disease heterogeneity [ Time Frame: Within 2 weeks after imaging procedures ]
    CT guided or Ultra Sound guided biopsies from PET/ DWI positive sites. Pathoanatomical and immunohistochemical findings and gene expression data from positive sites are compared to random bone marrow.

  2. Early signs of bone remodeling [ Time Frame: "baseline", after induction treatment and after end of treatment ]
    18F-natrium-fluoride-PET/CT is performed at time of diagnosis (baseline) during week 1-2, after induction treatment and after end of treatment. We test if increased 18F-natrium-fluoride uptake is seen in bone sites where, according to CT and DWI, no abnormal bone remodeling is taking place and we observe the association between FDG-PET and fluoride-PET and markers of bone metabolism. We use descriptive statistics for number of bone sites with increased fluoride uptake, 95% Confidence interval



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Prospective study with 60 patients referred to Haematological Department under the suspicion of having treatment demanding multiple myeloma. Patients will be included from two centres of Haematology.
Criteria

Inclusion Criteria:

  1. Male or female subjects > 50 years at time of signing informed consent.
  2. Subject under suspicion of having treatment demanding multiple myeloma in concordance with Danish cancer package criteria
  3. Signed informed consent before performance of any study related procedures.
  4. Subject is willing and able to comply with the protocol as judged by the investigator.

Exclusion Criteria:

  1. Formerly treated multiple myeloma.
  2. Known inflammatory disease, recent biological therapies or chemotherapy for non-malignant disease (less than 3 months prior to screening), clinically relevant active infection.
  3. Concurrent or recent radiotherapy or surgery less than two weeks prior to screening
  4. Glucocorticoid treatment exceeding 10 mg Prednisolone daily, less than two weeks prior to screening.
  5. Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at an unacceptable risk if s/he were to participate in the study, e.g. high levels of liver-enzymes and creatinine.
  6. Female subject is pregnant or breast feeding.
  7. Serious co-morbidity, and other medical or psychiatric illness likely to interfere with participation in this clinical study.
  8. Uncontrolled diabetes at the discretion of the investigator.
  9. Known or prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer or in situ prostate cancer for which the subject has been disease free for at least three years.
  10. POEMS syndrome (plasma cell dyscrasia with poly-neuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes).
  11. Exclusion according to MRI procedure (metal implants, claustrophobia, pace-maker).
  12. Exclusion according to biopsy study (thrombocytes < 50x /L, activated partial thromboplastin time(APTT) > 40 sec, and international normalized ratio(INR) > 1.5)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02187731


Locations
Denmark
Odense University Hospital
Odense C, Denmark, 5000
Sponsors and Collaborators
Odense University Hospital
Investigators
Principal Investigator: Brian Oestergaard, MD Odense University Hospital

Responsible Party: Brian Oestergaard, MD, Odense University Hospital
ClinicalTrials.gov Identifier: NCT02187731     History of Changes
Other Study ID Numbers: S-20120209
13/24748 ( Registry Identifier: Danish Dataprotection Agency )
First Posted: July 11, 2014    Key Record Dates
Last Update Posted: August 29, 2018
Last Verified: August 2018

Keywords provided by Brian Oestergaard, Odense University Hospital:
Multiple Myeloma
Functional Imaging
PET/CT
Diffusion Weighted MRI

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Body Weight
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Signs and Symptoms